SCHEMBL615353

SCHEMBL615353

CCn1c(C)nc2cc(NS(=O)(=O)c3cccc(Cl)c3C)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
APOBEC3A P31941 1/20 0.57
APOBEC3G Q9HC16 1/20 0.57
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
HSD11B1 P28845 2/20 0.47
MEN1 O00255 3/20 0.47
CYP1A2 P05177 3/20 0.47
KMT2A Q03164 3/20 0.47
NR1I2 O75469 3/20 0.47
CYP2C9 P11712 2/20 0.47
GAA P10253 2/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615834 0.92 KDM4E (0.49) KDM4EAPOBEC3AAPOBEC3GHSD11B1MEN1
SCHEMBL622613 0.89 KMT2A (0.52) KDM4EAPOBEC3AAPOBEC3GNPC1RAB9A
SCHEMBL13248536 0.89 HSD11B1 (0.45) KDM4EAPOBEC3AAPOBEC3GHSD11B1MEN1
SCHEMBL617578 0.89 HSD11B1 (0.45) KDM4EAPOBEC3AAPOBEC3GHSD11B1MEN1
SCHEMBL618667 0.89 NR1I2 (0.56) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL617197 0.86 PKM (0.44) KDM4EAPOBEC3AAPOBEC3GNPC1RAB9A
SCHEMBL616054 0.86 NPC1 (0.53) KDM4ENPC1RAB9AHSD11B1MEN1
SCHEMBL617451 0.84 HSD11B1 (0.48) HSD11B1MEN1KMT2ANR1I2LMNA
SCHEMBL12945240 0.82 NR1I2 (0.45) KDM4EAPOBEC3AAPOBEC3GHSD11B1MEN1
SCHEMBL617649 0.82 NPC1 (0.54) KDM4ENPC1HSD11B1NR1I2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 KDM4E 2033/4885APOBEC3A 4358/4885APOBEC3G 4359/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 KDM4E 565/4885APOBEC3A 2912/4885APOBEC3G 2544/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 KDM4E 565/4885APOBEC3A 2912/4885APOBEC3G 2544/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 KDM4E 893/4885APOBEC3A 3202/4885APOBEC3G 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.